178 related articles for article (PubMed ID: 31093562)
1. Standard and competing risk analysis of the effect of albuminuria on cardiovascular and cancer mortality in patients with type 2 diabetes mellitus.
Feakins BG; McFadden EC; Farmer AJ; Stevens RJ
Diagn Progn Res; 2018; 2():13. PubMed ID: 31093562
[TBL] [Abstract][Full Text] [Related]
2. Accounting for the Competing Risk of Death to Predict Kidney Failure in Adults With Stage 4 Chronic Kidney Disease.
Al-Wahsh H; Tangri N; Quinn R; Liu P; Ferguson Ms T; Fiocco M; Lam Md MSc NN; Tonelli M; Ravani P
JAMA Netw Open; 2021 May; 4(5):e219225. PubMed ID: 33944922
[TBL] [Abstract][Full Text] [Related]
3. What Is the Effect of Using a Competing-risks Estimator when Predicting Survivorship After Joint Arthroplasty: A Comparison of Approaches to Survivorship Estimation in a Large Registry.
Cuthbert AR; Graves SE; Giles LC; Glonek G; Pratt N
Clin Orthop Relat Res; 2021 Feb; 479(2):392-403. PubMed ID: 33105301
[TBL] [Abstract][Full Text] [Related]
4. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis.
Baena-Díez JM; Peñafiel J; Subirana I; Ramos R; Elosua R; Marín-Ibañez A; Guembe MJ; Rigo F; Tormo-Díaz MJ; Moreno-Iribas C; Cabré JJ; Segura A; García-Lareo M; Gómez de la Cámara A; Lapetra J; Quesada M; Marrugat J; Medrano MJ; Berjón J; Frontera G; Gavrila D; Barricarte A; Basora J; García JM; Pavone NC; Lora-Pablos D; Mayoral E; Franch J; Mata M; Castell C; Frances A; Grau M;
Diabetes Care; 2016 Nov; 39(11):1987-1995. PubMed ID: 27493134
[TBL] [Abstract][Full Text] [Related]
5. Assessing risk factors of non-fatal outcomes amid a competing risk of mortality: the example of hip fracture.
Buzkova P; Barzilay JI; Mukamal KJ
Osteoporos Int; 2019 Oct; 30(10):2073-2078. PubMed ID: 31256203
[TBL] [Abstract][Full Text] [Related]
6. Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study.
Fangel MV; Nielsen PB; Kristensen JK; Larsen TB; Overvad TF; Lip GY; Jensen MB
Am J Med; 2020 Jun; 133(6):e269-e279. PubMed ID: 32205071
[TBL] [Abstract][Full Text] [Related]
7. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes.
Lim HJ; Zhang X; Dyck R; Osgood N
BMC Med Res Methodol; 2010 Oct; 10():97. PubMed ID: 20964855
[TBL] [Abstract][Full Text] [Related]
8. Associations of mortality and cardiovascular disease risks with diabetes and albuminuria in urban Indigenous Australians: the DRUID follow-up study.
Barr ELM; Cunningham J; Tatipata S; Dunbar T; Kangaharan N; Guthridge S; Li SQ; Condon JR; Shaw JE; O'Dea K; Maple-Brown LJ
Diabet Med; 2017 Jul; 34(7):946-957. PubMed ID: 28375555
[TBL] [Abstract][Full Text] [Related]
9. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
Chang YH; Li WH; Chang Y; Peng CW; Cheng CH; Chang WP; Chuang CM
BMC Cancer; 2016 Mar; 16():235. PubMed ID: 26988703
[TBL] [Abstract][Full Text] [Related]
10. Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM
Brunekreef B; Strak M; Chen J; Andersen ZJ; Atkinson R; Bauwelinck M; Bellander T; Boutron MC; Brandt J; Carey I; Cesaroni G; Forastiere F; Fecht D; Gulliver J; Hertel O; Hoffmann B; de Hoogh K; Houthuijs D; Hvidtfeldt U; Janssen N; Jorgensen J; Katsouyanni K; Ketzel M; Klompmaker J; Hjertager Krog N; Liu S; Ljungman P; Mehta A; Nagel G; Oftedal B; Pershagen G; Peters A; Raaschou-Nielsen O; Renzi M; Rodopoulou S; Samoli E; Schwarze P; Sigsgaard T; Stafoggia M; Vienneau D; Weinmayr G; Wolf K; Hoek G
Res Rep Health Eff Inst; 2021 Sep; 2021(208):1-127. PubMed ID: 36106702
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
12. Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
[TBL] [Abstract][Full Text] [Related]
13. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
[TBL] [Abstract][Full Text] [Related]
14. Considerations of Competing Risks Analysis in Cardio-Oncology Studies:
Li Y; Sun L; Burstein DS; Getz KD
JACC CardioOncol; 2022 Sep; 4(3):287-301. PubMed ID: 36213358
[TBL] [Abstract][Full Text] [Related]
15. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus.
Valmadrid CT; Klein R; Moss SE; Klein BE
Arch Intern Med; 2000 Apr; 160(8):1093-100. PubMed ID: 10789601
[TBL] [Abstract][Full Text] [Related]
16. Different survival analysis methods for measuring long-term outcomes of Indigenous and non-Indigenous Australian cancer patients in the presence and absence of competing risks.
He VY; Condon JR; Baade PD; Zhang X; Zhao Y
Popul Health Metr; 2017 Jan; 15(1):1. PubMed ID: 28095862
[TBL] [Abstract][Full Text] [Related]
17. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
Nolan EK; Chen HY
Arch Osteoporos; 2020 Jun; 15(1):86. PubMed ID: 32519193
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the Absolute Risk of Cardiovascular Disease and Other Events: Issues With the Use of Multiple Fine-Gray Subdistribution Hazard Models.
Austin PC; Putter H; Lee DS; Steyerberg EW
Circ Cardiovasc Qual Outcomes; 2022 Feb; 15(2):e008368. PubMed ID: 35098725
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
